Outset Medical, Inc. (NASDAQ:OM – Get Free Report)’s stock price passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $4.13 and traded as high as $4.24. Outset Medical shares last traded at $4.23, with a volume of 38,604 shares trading hands.
Wall Street Analyst Weigh In
OM has been the topic of several recent analyst reports. Weiss Ratings downgraded Outset Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. Wall Street Zen raised Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $10.00.
View Our Latest Analysis on OM
Outset Medical Stock Up 3.2%
The company has a market capitalization of $79.82 million, a P/E ratio of -1.09 and a beta of 1.93. The company has a quick ratio of 4.11, a current ratio of 4.86 and a debt-to-equity ratio of 1.19. The firm has a fifty day simple moving average of $3.73 and a 200-day simple moving average of $4.13.
Outset Medical (NASDAQ:OM – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. The business had revenue of $33.60 million during the quarter, compared to analysts’ expectations of $31.40 million. Outset Medical had a negative return on equity of 66.98% and a negative net margin of 58.33%. On average, equities research analysts expect that Outset Medical, Inc. will post -3.81 EPS for the current fiscal year.
Institutional Investors Weigh In On Outset Medical
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC acquired a new position in Outset Medical during the second quarter worth $98,000. Bank of New York Mellon Corp bought a new stake in shares of Outset Medical in the 2nd quarter valued at about $121,000. Marquette Asset Management LLC bought a new stake in shares of Outset Medical in the 2nd quarter valued at about $212,000. Renaissance Technologies LLC grew its holdings in Outset Medical by 391.3% during the first quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock worth $853,000 after purchasing an additional 176,870 shares during the period. Finally, Sei Investments Co. lifted its position in shares of Outset Medical by 15.5% in the first quarter. Sei Investments Co. now owns 35,366 shares of the company’s stock valued at $136,000 after buying an additional 4,738 shares during the last quarter.
About Outset Medical
Outset Medical, Inc is a medical technology company that develops products for hemodialysis, a treatment that filters waste and excess fluid from the blood when the kidneys are no longer able to do so adequately. The company’s primary product is the Tablo Hemodialysis System, an integrated dialysis platform designed to simplify treatment for healthcare providers and support broader use of dialysis in hospitals, outpatient facilities and the home.
The Tablo system combines dialysis delivery, water purification and dialysate production in a single device and uses a touchscreen interface intended to guide users through treatment setup and operation.
Featured Articles
- Five stocks we like better than Outset Medical
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.
